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A B S T R A C T
Adipose tissue regulates insulin sensitivity via the circulating adipocytokines, leptin, resistin
and adiponectin. Hypoadiponectinemia contributes to the development of obesity and related
disorders such as diabetes, hyperlipidemia, and cardiovascular diseases. In this study, we
investigated the effects of Brazilian propolis on adiponectin levels in type 2 diabetes mel-
litus (T2DM), the mechanism of signaling pathway was explored as well. T2DM was induced
in male Wistar rats using high fat diet and low dose of streptozotocin (STZ, 35 mg/kg, i.p.).
Propolis was administered by oral tubes. Peroxisome proliferator activated receptor gamma
(PPARγ) levels in sub abdominal adipose tissue, serum levels of adiponectin, tumor necro-
sis factor-α (TNF-α) and insulin were detected by Enzyme Linked ImmunosorbentAssay (ELISA).
Malondialdehyde (MDA) and reduced glutathione (GSH) in sub abdominal adipose tissue,
fasting plasma glucose, plasma triglycerides and total cholesterol levels were measured by
colorimetric method. Results showed that Brazilian propolis ameliorated hypoadiponectinemia
inT2DM rats and relieved high glucose-induced adiponectin decrease.The signaling pathway
analysis indicated that PPARγ regulation was involved. In conclusion, Brazilian propolis could
have beneficial effect in T2DM by increasing tissue PPARγ levels, restoring serum adiponectin
levels, enhancing insulin sensitivity and subsequently, attenuating elevated glucose level.
© 2015 Mansoura University. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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1. Introduction
It is undeniable to say that there are more than 194 million
people with diabetes worldwide [1,2]. Diabetes mellitus is char-
acterized by high blood glucose levels and is associated with
devastating and life-threatening complications that affect
various body organs, such as blood vessels, eyes, kidneys and
nerves [3,4]. Among different types of diabetes mellitus, Type
2 account for 90% of diagnosed patients. Type 2 diabetes
mellitus (T2DM) is a metabolic syndrome, which is character-
ized by both fat accumulation and impairment in insulin
action, insulin production, or both; a condition called insulin
resistance. Insulin resistance leads to the development of
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hyperglycemia. Such harmful hyperglycemia produced tissue
damaging glucotoxicity, which is the major cause of diabetic
complications [5]. In addition, abnormal metabolism of accu-
mulated fat in adipose tissues can cause lipotoxicity, which can
further exacerbate diabetic complications [6].
Themanagement ofT2DM entails lifestyle modification and/
or pharmaceutical treatment such as insulin, biguanides,
sulfonylureas, and alpha glucosidase inhibitors. However, these
anti-diabetic medications are far from being satisfactory because
of limited efficacy and many undesirable side effects [7]. As a
consequence, T2DM is still an incurable disease with poor
quality of life, high morbidity and mortality.Thereby, the social
and economic burdens of this disease pose an urgent need for
development of novel therapeutic strategies for treatment with
satisfactory efficacy and no adverse effects [8].
Adipose tissue secretes many proteins and hormones such
as adipocytokines, resistin, leptin, and adiponectin to control
insulin sensitivity [9]. Adiponectin is a protein hormone se-
creted into the blood stream in average 0.01% of total
plasma proteins.The important role of adiponectin comes from
modulation of glucose and lipid metabolism in insulin sensi-
tive tissue [10,11]. Accumulating evidence showed that
hypoadiponectinemia played a key role in the pathogenesis of
obesity and related diseases [12,13]. Furthermore, adiponectin
administration to obese or diabetic mice can reduce body
weight and blood glucose levels while enhancing insulin sen-
sitivity [14,15]. Based on these data, adiponectin was conceived
to be a novel therapy target for obesity and insulin resistance
[16].
Various factors are involved in regulation of adiponectin ex-
pression. These factors include, peroxisome proliferator-
activated receptor (PPAR-γ), CCAAT-enhancer-binding protein
(C/EBP) α, Kruppel-like factor 7 (KLF7), and sterol regulatory
element binding protein-1c (SREBP-1c). Among these factors,
PPARγ is recognized as the master regulator of gene transcrip-
tion and plasma concentrations of adiponectin [9]. PPARγ binds
directly to a functional PPAR-responsive element (PPRE) in
adiponectin promoter, leading to enhancement of adiponectin
gene transcription [17]. Indeed, adiponectin was believed to be
a marker for activity of PPARγ [18].
Propolis (Brazilian) is a sticky resinous mixture that honey
bees collect from tree buds, sap flows, or other botanical sources.
Its color varies depending on its botanical source, the most
common being dark brown [19]. The chemical compositions
of propolis are mainly flavonoids, aromatic acids and esters,
aldehydes and ketones, fatty acids and esters, terpenes, ste-
roids, amino acids, polysaccharides, hydrocarbon, alcohol,
hydroxybenzene and other compounds [20]. Brazilian propo-
lis composed mainly of phenolic compounds artepillin C.
Besides, it was reported to contain 3-prenyl-4-hydroxycinnamic,
p-coumaric, caffeic acid, and caffeoylquinic acids, cinnamic
acids and the flavonoids pinobanksin and kaempferol [21]. Bra-
zilian propolis has been reported to possess various biological
activities including antioxidant, anti-microbial, liver protec-
tive, immunoregulatory, anti-inflammatory, and anticancer
effects [22]. In addition, it was reported to have hypoglycemic
and hypolipidemic effects. Further, propolis was also demon-
strated to control metabolic disorders in diabetic rats and to
accelerate the tissue regeneration and repair of damaged pan-
creatic cell [23].
A recent study demonstrated that Brazilian propolis re-
stored obesity-induced down regulation of adiponectin
expression. In view of this recent claim, we investigated the
effect of Brazilian propolis on adiponectin levels in T2DM
induced experimentally in rats [24]. The signaling pathway
mechanism was explored along with the regulatory roles of
PPARγ.
2. Materials and methods
2.1. Ethics statement
Experimental design and animal handling were according to
the guidelines of the Ethical Committee of the Faculty of Phar-
macy, Mansoura University, for Animal Use.
2.2. Animals
Male Sprague Dawley rats (160–180 mg) were housed in a cer-
tified animal care at a constant temperature (22 °C) under a
12-hour light–dark cycle, and were provided with standard rat
food and water.
2.3. Experimental design
The rats were randomly divided into 3 groups with two dietary
regimens. Group1 (control group) was fed certified standard
chow; Group2 (diabetic untreated group) was fed high fat (HF)
diet. Group3 (diabetic group treated by Brazilian propolis) was
fed HF diet for an initial period of 2 weeks without treatment.
HF diet consists of (58% fat, 25% protein and 17% carbohy-
drate, as a percentage of total kcal) [25]. After the 2 weeks of
dietary manipulation, the rats from group 2 and 3 were in-
jected intraperitoneally (i.p.) with low dose of STZ (Sigma-
Aldrich Co, St Louis,MO) (35 mg kg−1) after overnight fasting [26].
The rats with blood glucose levels ≥250 mg/dl were considered
diabetic and selected for further studies.The rats were allowed
to continue to feed on their respective diets until the end of the
study [27].Type 2 diabetic rats in group 3were treatedwith propo-
lis (in aqueous solution, 0.6 g/kg), by oral tube for 21 days. The
dose used for propolis in this study was in the range used in
other studies applied for the same animal species [28].
At the end of the study, the rats were fasted overnight, and
then sacrificed. Blood samples were collected via puncture of
retro-orbital venous plexus using heparinized capillary hema-
tocrit tubes. Blood was centrifuged at 3000 rpm for 5 minutes,
and then plasma and serum samples were separated for de-
termination of the biochemical parameters. Rats’ sub abdominal
adipose tissues were isolated, weighed and then homog-
enized in a 10-fold volume of ice-cold sodium potassium
phosphate buffer (0.01 M, pH 7.4) containing 1.15% KCl. The
homogenates were centrifuged at 3000 rpm at 4 °C for 10
minutes and immediately used for determination of oxida-
tive stress or stored at −80 °C until used.
2.4. Assessment of biochemical parameters
Fasting plasma glucose concentrations were determined using
the glucose oxidase method, and Triglyceride (TG) and total
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cholesterol (TC) were assayed using calorimetric kits pur-
chased from Biodiagnostic Company (Egypt, Cairo), according
to manufacturer’s instructions.
2.5. Assessment of oxidative stress
Malondialdehyde (MDA) and reduced glutathione (GSH) were
estimated in sub abdominal adipose tissue using commer-
cial kits from Biodiagnostic Company (Egypt, Cairo), according
to manufacturer’s instructions.
2.6. Enzyme-linked immunosorbent assay (ELISA)
ELISA technique was used to assess serum adiponectin con-
centration, serum tumor necrosis factor-α (TNF-α), circulating
insulin and PPARγ concentration in sub abdominal adipose
tissue according to manufacturer’s instructions.The kits were
purchased from MyBioSource Company (5520 Hubner Rd, San
Diego, CA 92105, United States).
2.7. Statistical analysis
Results are expressed as means ± SEM of 6 animals, and dif-
ferences between groups were tested for significance using
analysis of variance (ANOVA), followed byTukey’s post hoc test.
The level of statistical significance was taken at P ≤ 0.05. Sta-
tistical analysis of the experimental data was performed using
the statistical package SPSS as the definitive analyzer of drug
effects.
3. Results
3.1. Effect of Brazilian propolis on body Weight and Sub
abdominal adipose tissue weight
As shown in Fig. 1A, B, diabetes induction resulted in signifi-
cant decrease in body weight by 25.25% and marked reduction
in sub abdominal adipose tissue weight by 43.49% without af-
fecting the food intake compared to control group. However,
propolis treatment increased body weight by 1.05 folds and sub
abdominal adipose tissue weight by 1.07 folds without affect-
ing the food intake compared to diabetic group.
3.2. Effect of Brazilian propolis on fasting blood glucose
and fasting insulin levels
Fasting blood glucose and fasting serum insulin levels (M ± SE)
in diabetic and control groups are illustrated in Fig. 2A, B. Fasting
blood glucose increased 4.48 fold in diabetic group when com-
pared to control group. Besides, fasting serum insulin increased
2.05 folds in diabetic group when compared to control group.
Propolis treatment reduced fasting blood glucose level by 69.52%
and reduced fasting insulin level by 50% compared to dia-
betic group.
3.3. Effect of Brazilian propolis on lipid profile
The effects of propolis on lipid profile in rats are given in Table 1.
The results showed that propolis treatment significantly in-
creased the serum levels of high density lipoprotein 3.99 fold
Table 1 – Effect of Brazilian propolis treatment on the level of total cholesterol, total lipids, high-density lipoprotein
cholesterol, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, Triglyceride (TG) in rats with
type 2 induced diabetes mellitus (Mean ± SE).
GROUP Triglyceride
mg/dl
Total cholesterol
mg/dl
HDL-cholesterol
mg/dl
LDL-cholesterol
mg/dl
VLDL-cholesterol
mg/dl
Total lipids
mg/dl
Control group 102.2 ± 9.22 137 ± 4.6 65.4 ± 4 51 ± 5.85 20.4 ± 1.91 254 ± 16
Diabetic group 366.4 ± 14.47* 238 ± 8.25* 26.28 ± 7.3* 110.8 ± 4.9* 73.2 ± 2.85* 1344 ± 196*
Propolis group 145.4 ± 22.54# 182.4 ± 12.6# 104.8 ± 15.5# 57.4 ± 4.97# 28.8 ± 4.55# 457.2 ± 63#
* Significant compared to control group, p < 0.05.
# Significant compared to diabetic group, p < 0.05.
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Fig. 1 – Effects of Brazilian propolis treatment on (A) total
weight and (B) sub abdominal adipose tissue weight.
*Significant compared to control group, p < 0.05.
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compared to diabetic group. In parallel, propolis treatment
markedly decreased low density lipoprotein, total choles-
terol, triglyceride, total lipid and very low density lipoprotein
compared to diabetic group (P < 0.05).
3.4. Effects of Brazilian propolis on oxidative stress
Lipid peroxides in sub abdominal adipose tissue were mea-
sured as MDA. Results showed that MDA increased 4.78 fold
in diabetic group when compared to control group. However,
Propolis treatment reduced MDA by 58.5% compared to dia-
betic group, Fig. 3A. On the other hand, diabetes significantly
reduced GSH levels in sub abdominal adipose tissue of dia-
betic rats by 31.3% compared to control group. Propolis
treatment restored GSH levels in sub abdominal adipose tissue
of treated group compared to diabetic group (P < 0.05), Fig. 3B.
3.5. Effect of Brazilian propolis treatment on TNF-α
As illustrated in Fig. 4, serum TNF-α level increased 5.89 fold
in diabetic group when compared to control group. However,
propolis treatment reduced TNF-α by 59.78% compared to dia-
betic group.
3.6. Effect of Brazilian propolis treatment on adiponectin
and PPARγ concentration
As illustrated in Fig. 5A, B, serum adiponectin decreased by
63.01% in the diabetic group when compared to control group.
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Fig. 2 – Effect of Brazilian propolis treatment on (A) fasting
blood glucose and (B) fasting insulin levels. *Significant
compared to control group, p < 0.05. #Significant compared
to diabetic group, p < 0.05.
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Fig. 3 – Effect of Brazilian propolis treatment on (A) MDA in
sub abdominal adipose tissue and (B) GSH in sub
abdominal adipose tissue. *Significant compared to control
group, p < 0.05. #Significant compared to diabetic group,
p < 0.05.
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Fig. 4 – Effect of Brazilian propolis treatment on serum
TNF-α. *Significant compared to control group, p < 0.05.
#Significant compared to diabetic group, p < 0.05.
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In addition, sub abdominal adipose tissue (PPAR-γ) levels de-
creased by 87.71% in diabetic group when compared to control
group. On the other hand, propolis treatment markedly in-
creased the serum levels of adiponectin 3 folds and increased
the concentration of PPARγ 1.9 fold compared to diabetic group.
3.7. Correlation analysis of studied parameters
Results illustrated in Fig. 6 showed that fasting blood glucose
level negatively correlated with serum adiponectin (r = −0.3,
p < 0.05) and PPAR-γ levels (r = −0.7, p < 0.05). In addition, serum
adiponectin positively correlated with PPAR-γ (r = 0.677, p < 0.05)
and HDL-cholesterol (r = 0.77, p < 0.05) and GSH (r = 0.869,
p < 0.05).Moreover, serum adiponectin correlated negatively with
insulin (r = −0.765, p < 0.05), total lipids (r = −0.86, p < 0.05), MDA
(r = −0.82, p < 0.05).
4. Discussion
The results of the present investigation confirmed earlier reports
that propolis treatment could almost control the hyperglyce-
mia in the STZ-induced diabetic rat model [29]. The glycemic
control achieved by Brazilian propolis treatment could be due
to increasing adiponectin levels, up-regulation of PPARγ levels
and enhancing insulin sensitivity.
At the first steps, diabetes induction by STZ caused rapid
reduction in body weight. This was in agreement with previ-
ous reports [30]. The body weight loss in diabetic rats could be
explained by many reasons, including dehydration as well as
excessive fats and proteins catabolism [31], which ultimately
leads to muscle wasting [32]. On the contrary, propolis treated
rats showed non significant increase in body weight com-
pared to control group, which could be attributed to better
control of hyperglycemic state compared to the untreated dia-
betic group.
Several studies have documented the association between
diabetes mellitus and abnormalities in lipid metabolism [33].
Dyslipidemia is believed to be a major risk factor for devel-
opment of various diabetic complications. Diabetes-associated
dyslipidemia resulted from excessive production of free fatty
acids along with abnormal lipoprotein metabolism. Hence, dia-
betes mellitus is associated with an increase in TG and LDL,
and decrease in HDL [34]. Similarly, the results of our inves-
tigation revealed disturbance in lipid metabolism in diabetic
untreated rats.These effects were attenuated by propolis treat-
ment. Of note, our findings provide ample support to the notion
that propolis preparations could modulate lipid metabolism
[35].
Insulin resistance is considered as a hallmark of T2DM.Ac-
cumulated fat in different body cells disturb their response to
insulin, leading to insulin resistance and elevated blood glucose
levels [36]. Previous studies have convincingly showed that
propolis treatment decreased insulin resistance in obese dia-
betic rats [37]. In addition, propolis was found to enhance
translocation of glucose transporter 4 and glucose uptake in
mouse myocyte cell lines, as well as in the ICR mouse strain
[38]. In confirmation with these reports, our results demon-
strated that propolis markedly reduced fasting plasma glucose
level in treated rats compared to untreated diabetic groups.This
suggested that propolis could be a beneficial anti-hyperglycemic
agent in T2DM.
As already noted, lipid peroxidation plays a significant role
among oxidative defects that damages β cells inT2DM [39]. Con-
vincing evidence has established a link between oxidative stress
and insulin resistance. Increased free radical levels have del-
eterious effects on β cells, including decreased insulin secretion
in response to glucose, impaired gene expression and cell death,
leading ultimately to hyperglycemia and diabetes [40]. More-
over, Elevated free radical concentrations stimulate various
signaling pathways that lead eventually to degradation of insulin
receptors [41]. Therefore, targeting oxidative stress could be a
potential therapeutic approach in T2DM. In the present study,
diabetic treated rats showed significantly lower MDA levels and
restored GSH levels nearing normal control values.This finding
is consistent with the earlier report that propolis caused the
partial restoration of β-cell function, possibly by an antioxi-
dant defense mechanism [42]. Therefore, the protective
mechanism of propolis against HF-induced diabetic changes
could be attributed to its potent anti-oxidative properties.
In addition to oxidative stress, inflammation is consid-
ered an important pathogenic factor in the development of
insulin resistance in T2DM. Oxidative stress and endoplas-
mic reticulum stress stimulate inflammatory signaling inT2DM.
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Fig. 5 – Effect of Brazilian propolis treatment on serum
adiponectin and PPARγ in sub abdominal adipose tissue.
*Significant compared to control group, p < 0.05. #Significant
compared to diabetic group, p < 0.05.
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Fig. 6 – (A) Negative correlation between fasting blood glucose level and serum adiponectin (r = −0.3, p < 0.05) as well as
PPARγ levels (r = −0.7, p < 0.05). (B) Positive correlation between adiponectin level and PPARγ (r = 0.677, p < 0.05),
HDL-cholesterol level (r = 0.77, p < 0.05) and GSH level (r = 0.869, p < 0.05). (C) Negative correlation between adiponectin level
and serum insulin (r = −0.765, p < 0.05), serum total lipids (r = −0.86, p < 0.05) and tissue MDA levels (r = −0.82, p < 0.05).
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Inflammatory stimuli, in turn activate multiple serine/threonine
kinases that inhibit insulin signaling [43]. Specifically, TNF-α
was strongly linked to insulin resistance and diabetes. TNF-α
increases free fatty acids production, interferes with insulin
receptor signaling, decreased insulin sensitivity and inhibit
adiponectin synthesis [44]. Our results showed that diabetes
markedly increased serumTNF-α compared to control group.
Propolis treatment reduced TNF-α level in treated diabetic rat.
These results are in agreement with other studies that re-
ported anti-inflammatory properties of propolis [45].
Adipose tissue is an endocrine organ that plays a crucial
role in pathophysiology of T2DM [46]. Adiponectin is defined
as anti-diabetic hormone secreted by adipose tissue.
Adiponectin was shown to be associated with various meta-
bolic disorders, including obesity, insulin resistance, and obesity
related cardiovascular and fatty liver diseases [47]. Moreover,
adiponectin production was reported to be negatively corre-
lated with accumulated visceral fat [48]. Further, reduced
adiponectin levels were observed in obesity [49] and knock-
ing out adiponectin resulted in severe insulin resistance and
diabetes [50]. Similarly, our results showed reduced levels of
adiponectin in diabetic rats. Interestingly, adiponectin levels
in our study were inversely correlated to the levels of blood
glucose, insulin, total lipids and MDA. On the other hand, a high
adiponectin level is found to be a consistent indicator of lower
risk of T2DM because of its anti-diabetic and anti-atherogenic
effects [51]. In line with this study, our results revealed that
propolis restored reduced adiponectin levels in treated dia-
betic rats compared to untreated diabetic rats.
This finding led us to study how propolis may lead to down
regulation of adiponectin expression. Gene expression of
adiponectin is mainly regulated by nuclear transcriptor PPARγ.
PPARγ is known to regulate adipocyte differentiation and to
control the transcription of many adipocyte-specific genes. Re-
search demonstrated that PPARγ agonists increased the
circulating adiponectin in high fructose fed rat model [52].
Hence, adiponectin expression was believed to be a pertinent
target for PPARγ agonists. In addition, epidemiological study
proved that PPARγ gene polymorphismwould reduce the serum
adiponectin levels [53]. In the present investigation, de-
creased protein concentration of PPARγ and adiponectin was
observed in diabetic rats.These adverse changes were counter
regulated by propolis treatment.These results were further con-
firmed by the observed significant positive correlation between
PPARγ and adiponectin levels, suggesting PPARγ activation as
a possible pathway involved in propolis protective effect. More-
over, PPARγ activation was found to attenuate insulin resistance
by elevating the number of mature adipocytes, increasing
glucose disposal rate and decreasing circulating free fatty acids
levels [54]. In this context, our study revealed that both tissue
PPARγ and serum adiponectin levels negatively correlated with
fasting blood glucose level.
5. Conclusion
In conclusion, this study demonstrated that Brazilian propo-
lis can reverse changes evoked byT2DM induced experimentally
in rats, possibly by combating oxidative stress, activating PPARγ,
elevating adiponectin levels and reducing insulin resistance,
Fig. 7. This ability of Brazilian propolis to target various path-
ways involved in T2D makes it a promising therapy for
management of T2D.
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